Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment，and to evaluate the effectiveness and safety on clinical and structural change of AS patients with different treatments after 24 weeks.
A total of 92 active ankylosing spondylitis patients were included, disease activity was defined as the following three aspects: BASDAI ≥ 4 or ASDAS≥ 2.1；CRP＞6 mg/L or ESR 28 mm/1st hour；more than 2 and less than 16 syndesmophyts between cervical spine and lumber spine detected by X-ray. All patients were randomly assigned （1：1：1）to one of the three treatment groups：celecoxib 200mg bid，etanercept 50mg qw and combined therapy for 24 weeks. Disease activity was assessed with BASDAI and ASDAS, ASAS response rate was used for the evaluation of clinical efficacy. Structural change was detected using the mSASSS and SIJ SSS, and inflammation was assessed by SIJ SPARCC.
Results: A total of 92 active AS patients were included, the average age was 32.02 with mean disease duration of 9 years, the positive rate of HLA-B27 was 94.8%. The average syndesmophyts was 5.61 per patient, mSASSS and SIJ SPARCC score was 8.76 and 15.13 respectively in baseline. Erosion, fat metaplasia, backfill and ankylosis score of SSS was 3.26, 5.26, 1.09 and 3.26. After completing 24 weeks’ treatment, the ASAS20 response in celecoxib, etanercept and combined group are 69.2%, 71.8% and 88.2% respectively. Of the three groups, 46.1%, 65.6% and 70.6% of patients fulfilled ASAS40 response, and almost half of patients acquired ASDAS major change. The back pain score, BASDAI, BASFI and ASDAS of three different treatment groups decreased as time extend, the combined therapy group obtained most significant change. After 24 weeks, SIJ and spine SPARCC inflammation score decreased sharply, and no statistical difference was found between three groups in four indexes of SSS. Adverse events such as upper respiration infection and slightly elevated ALT were more seen in the combined group and no SAE occurred during the research.
Conclusion: Etanercept and celecoxib alone/combined treatment were efficacious and safe in improving the symptom and sign of active AS patients, combined therapy group had the best result. The use of etanercept can alleviate inflammation detected by MRI, there were no difference of structural change between the three groups.
To cite this abstract in AMA style:Gu J, Tu L, Zhao M, Lin Z, Liao Z, Cao S, Yu Q, Ye Z. A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-multi-center-open-label-randomized-clinical-tries-of-etanercept-and-celecoxib-alonecombined-treatment-in-effectiveness-and-safety-of-ankylosing-spondylitis/. Accessed November 27, 2022.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multi-center-open-label-randomized-clinical-tries-of-etanercept-and-celecoxib-alonecombined-treatment-in-effectiveness-and-safety-of-ankylosing-spondylitis/